The Pharma & Healthcare industry is of vital importance for human and economic development, providing a wide range of goods and services relevant to the promotion of health at all stages in the healthcare process – from prevention and treatment to rehabilitation and palliative care. It is one of the fastest-growing industries, supported by profound demographic changes, the rising incidence of non-communicable diseases, and surging per capita health spending in both developed and emerging markets. The industry is also one of the major innovators, with increasing expenditures on development of new molecules, biotechnology and adoption of new technologies that provide advanced healthcare and ensure the longevity of the population.
The Pharma & Healthcare industry comprises the manufacture of pharmaceuticals for human and veterinary use, medical equipment and related supplies. It also includes providers of ambulatory health services, medical and diagnostic laboratories, hospitals, and nursing and residential care facilities.
China’s healthcare sector kept growing over the second quarter of 2019. The period was characterised by increased government spending on healthcare, with the amount dedicated to health and family planning rising by 5.9% y/y to RMB 534.5bn in Q2 ...View more details
The first quarter of 2019 witnessed a continuous growth of China’s healthcare sector. The country promoted the implementation of the Healthy China Initiative, as well as ongoing structural reforms in the sector. The period was characterized by ...View more details
The changing demographic and disease profiles of Hungary were the drivers of the expansion of health expenditure in recent years. As a result, the country spent 7.4% of its GDP on healthcare in 2016, still below the EU average. The government ...View more details
China’s healthcare sector continued to grow in Q4 2018, largely stimulated by the expansion of online healthcare services. The growth was attributed to increasing demand for quality healthcare, driven by the country’s strong economic ...View more details
Turkey’s healthcare system has been fully reformed under the 2003-2013 Health Transformation Programme (HTP), which helped expand the coverage and quality of health services across the country. Health insurance coverage reached 98.4% of the ...View more details
China is the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large share of ageing ...View more details
The economy’s return to growth provided a strong impetus to the Russian healthcare sector in 2017. Healthcare expenditure grew by a robust 22% y/y, when measured in US dollar terms, the first increase in many years. However, at USD 92bn in 2017 ...View more details
With 1.4bn population each as of 2017, India and China are the most numerous countries out of the six forming the focus of this report. However, the two countries differ widely in terms of per capita GDP, with that of China being more than twice that ...View more details
Peru is a comparatively small pharmaceutical market in Latin America (ranking eighth in terms of sales volume in 2017), with a relatively young and growing population. However, public health spending is expanding at a rapid pace, particularly in ...View more details